InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,702.55
(
-0.19%
)
US TECH 100
19,287.60
(
-0.24%
)
Dow Jones
42,063.36
(
0.09%
)
Brent Oil
74.34
(
0.61%
)
Bitcoin
63,823.21
(
0.32%
)
Post# of 253175
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120476
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: 10nisman post# 133705

Friday, 12/23/2011 12:42:42 PM

Friday, December 23, 2011 12:42:42 PM

Post# of 253175
Musings on the MNTA-BAX deal:

The MNTA-BAX partnership can be quite lucrative* for MNTA if MNTA makes good on its claim of being able to develop interchangeable FoB’s for big-selling biologics such as Humira that no one else can. If, on the other hand, the partnership fails to accomplish this, the economic value of the collaboration to MNTA will be modest at best.

I would submit that the tepid investor response to the BAX deal (so far) is not due to a deficiency in the partnership’s financial terms, but rather to skepticism that MNTA can accomplish what it says it can accomplish with respect to interchangeability.

*See #msg-70236725, #msg-70237561, and #msg-70238965 for supporting arithmetic.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up